The endogenous cannabinoid system plays important roles in the retina of mice and monkeys via their classic CB1 and CB2 receptors. We have previously reported that the G protein-coupled receptor 55 (GPR55), a putative cannabinoid receptor, is exclusively expressed in rod photoreceptors in the monkey retina, suggesting its possible role in scotopic vision. To test this hypothesis, we recorded full-fi eld electroretinograms (ERGs) after the intravitreal injection of the GPR55 agonist lysophosphatidylglucoside (LPG) or the selective GPR55 antagonist CID16020046 (CID), under light-and dark-adapted conditions. Thirteen vervet monkeys ( Chlorocebus sabaeus ) were used in this study: four controls (injected with the vehicle dimethyl sulfoxide, DMSO), four injected with LPG and fi ve with CID. We analyzed amplitudes and latencies of the a-wave (photoreceptor responses) and the b-wave (rod and cone system responses) of the ERG. Our results showed that after injection of LPG, the amplitude of the scotopic b-wave was signifi cantly higher, whereas after the injection of CID, it was signifi cantly decreased, compared to the vehicle (DMSO). On the other hand, the a-wave amplitude, and the a-wave and b-wave latencies, of the scotopic ERG responses were not signifi cantly affected by the injection of either compound. Furthermore, the photopic ERG waveforms were not affected by either drug. These results support the hypothesis that GPR55 plays an instrumental role in mediating scotopic vision.
Introduction
The endocannabinoid (eCB) system, including eCBs, cannabinoid receptors, and enzymes regulating the level of eCBs, is present in the central nervous system of all mammals. In most cases, eCBs act as retrograde messengers binding to the widely distributed CB1 receptors (CB1Rs) to inhibit the neurotransmitter release at both excitatory and inhibitory synapses (Kreitzer & Regehr, 2001 a , b ; Ohno-Shosaku et al., 2001 ; Wilson & Nicoll, 2001 ; Freund et al., 2003 ; Yazulla, 2008 ) . In addition to the two main cannabinoid receptors [CB1R and CB2 receptor (CB2R)], G protein-coupled receptor 55 (GPR55) has been suggested as a cannabinoid receptor since it is activated by anandamide, an endogenous cannabinoid, and tetrahydrocannabinol, an exogenous cannabinoid (Ryberg et al., 2007 ) .
In fact, GPR55 is a receptor that is also responsive to other cannabinoids (Oka et al., 2007 ; Ryberg et al., 2007 ) . While GPR55 is implicated in several physiological and pathophysiological functions (Liu et al., 2015 ) , its role in the retina is as yet unknown. Early case reports in the 1970s suggested the existence of cannabis-mediated visual effects in humans, although the specifi c mechanisms or activation pathways are still not defi ned. Cannabis consumption can lead to an increase in glare recovery for low contrast stimuli (Adams et al., 1978 ) , a reduction in Vernier and Snellen acuities (Kiplinger et al., 1971 ; Adams et al., 1975 ) , blurred vision (Noyes et al., 1975 ) , and changes in color discrimination and photosensitivity (Dawson et al., 1977 ) . Given that most of these effects undoubtedly have a retinal component, recent investigations have focused on examining the endogenous cannabinoid system in the retina.
Cannabinoid receptor expression patterns are well documented in rodent and primate retinas (Yazulla et al., 1999 ; Straiker et al., 1999 a , b ; López et al., 2011 ; Zabouri et al., 2011 a , b ; Cécyre et al., 2013 ) , including vervet monkeys (Bouskila et al., 2012 , 2013 a , b ).
The latter species were used as the animal model to study the distribution of cannabinoid receptors in the retina and revealed cell-type specifi c expression profi les of CB1R, CB2R, and GPR55. While CB1R is present in retinal neurons (Bouskila et al., 2012 ) and CB2R is strictly expressed in glial Müller cells (Bouskila et al., 2013 a ) , GPR55 is exclusively found in rod photoreceptors (Bouskila et al., 2013 b ) . A variety of anatomical and functional visual effects of cannabinoids have also been reported for every retinal cell type in both rodents and fi sh (Yazulla, 2008 ; Cécyre et al., 2013 ) . However, these studies did not investigate GPR55 because of its recent and controversial deorphanization as a cannabinoid receptor (Henstridge et al., 2009 ) . Despite neuroanatomical and physiological evidence showing that the eCB system can modulate the activity of retinal cells in mammals, very little is known about the specifi c contribution of GPR55 in retinal functioning. Only one study has reported that palmitoylethanolamide can increase aqueous humor outfl ow through the trabecular meshwork, which appears to be mediated by GPR55 (Kumar et al., 2012 ) . This fi nding indirectly suggests that GPR55 plays a role in the eye.
Full-fi eld electroretinography is widely used as a measure of retinal function (McCulloch et al., 2015 ) . Electroretinogram (ERG) recordings represent the sum of electrical current over the entire retina, light-evoked responses in photoreceptors (cones and rods), neurons (horizontal cells, bipolar cells, amacrine cells, and ganglion cells), glial cells (Müller cells), and epithelial cells (Steinberg et al., 1985 ) . Amplitude, latency, and overall shape of the ERG waves depend on the intensity of the fl ash and its duration, as well as the adaptation state of the retina. While scotopic ERGs represent the contribution of the rod system in dark-adapted conditions, photopic ERGs represent the contribution of the cone system in light-adapted conditions. In the present study, we investigated the effect of the intravitreal injection of lysophosphatidylglucoside (LPG), an agonist of GPR55 (Guy et al., 2015 ) , or CID16020046 (CID), a selective GPR55 antagonist (Kargl et al., 2012 ) , on the dark-adapted and light-adapted full-fi eld ERGs in vervet monkeys. Given that GPR55 is exclusively expressed in rods (Bouskila et al., 2013 b ) , we hypothesized that the modulatory effect of GPR55 would manifest itself only in the ERG curves obtained in scotopic conditions.
Material and methods

Animals
A total of 13 adult vervet monkeys ( Chlorocebus sabaeus ) were used for this study: four monkeys received an intravitreal injection of dimethyl sulfoxide (DMSO, the vehicle), four monkeys were monocularly injected with LPG (a selective agonist of GPR55), and fi ve monkeys with CID (a potent and selective antagonist of GPR55) ( None of the animals were sacrifi ced for this study.
Animal preparation for ERG recording
The method for ERG recordings in the vervet monkey has been previously described (Bouskila et al., 2014 ) and is briefl y reported here. The animals were sedated with an intramuscular injection of a mixture of ketamine (10 mg/kg; Troy Laboratories, Glendenning, New South Wales, Australia) and xylazine (1 mg/kg; Lloyd Laboratories, Shenandoah, IA). This mixture has a minimal effect on the ERG (Nair et al., 2011 ) . The depth of sedation was maintained at a suffi cient level to prevent the animals from moving, but without causing respiratory depression. In this condition, the pupils were fully dilated to approximately 9 mm in diameter and the accommodation refl ex was paralyzed with topical application of 1% tropicamide (Mydriacyl ® ) and 2.5% phenylephrine hydrochloride (Mydfrin ® ) (Alcon Laboratories, Fort Worth, TX). Intraocular pressure was monitored before and after the recording session by applanation tonometry (TonoPen XL ® , Reichert Technologies, Depew, NY). The eyes were treated with 0.5% proparacaine hydrochloride (Alcaine ® , Alcon Laboratories, Fort Worth, TX) to anesthetize the cornea. The eyes were then protected by application of 2.5% methylcellulose (Gonak; Akorn, Inc., Buffalo Grove, IL) to prevent corneal drying. Body temperature was maintained between 36.5 and 38°C with a heating pad. Recording sessions lasted approximately 2 h for each animal, after which they were allowed to recover in their cage, and then returned to their prior naturalistic setting.
Drug administration
Intravitreal injections were performed in one eye only when the animals were in a sedated state. After inspection and examination of the eyes and lids, a topical anesthetic was applied over the injection site. The conjunctival and corneal surfaces were then moistened with methylcellulose (Moisture Eyes, Bausch Lomb, Rochester, NY) for 3 min. The eye was covered with sterile coatings and a Barraquer eye speculum (1.75 in., 10 mm wide small blades; Storz Ophthalmics, St Louis, MO) held the eyes open. The LPG was synthesized using the method described by Guy et al. ( 2015 ) , where its specifi city and selectivity were successfully tested on the spinal cord of mice and chicken. The antagonist CID was purchased from Tocris Bioscience (Cat. No. 4959, Ellisville, MO). With a 30G needle, 50 μ L of drug solution (LPG or CID) were injected into the vitreous cavity, 2 mm posterior to the corneal limbus. A similar volume (50 μ L) of the vehicle DMSO was injected into the vitreous of one eye in four control animals in order to rule out the possibilities that the injection per se and/or change in intraocular pressure caused the effects attributed to the drugs. When the needle was removed, the injection site was compressed for a minute using a sterile cotton swab to avoid refl ux. Before and after ERGs recordings, the fundi of both eyes were inspected with a PanOptic ophthalmoscope (Welch Allyn, New York, NY). The following week, topical antibiotic ointment was administered to the eye that had been injected, twice daily for 4 days.
Visual stimulation
Full-fi eld stimulation was produced with an UTAS BigShot Ganzfeld light source (UTAS E-3000 electrophysiology equipment; LKC Technologies, Inc., Gaithersburg, MD) that was placed in front of the animal's face. The intensity of the fl ashes ranged from 0.00025 to 790 (cd s)/m 2 delivered in full-fi eld conditions, with a duration of <5 ms. Xenon fl ash luminance of 2.5 to 790 (cd s)/m 2 (0-25 dB in LKC units) was used for photopic conditions and Light-Emitting Diode (LED) fl ash luminance of 2.5 × 10 −4 to 6 (cd s)/m 2 (−40 to 4 dB in LKC units) for scotopic conditions. Between stimuli, delay intervals of at least 15 s were implemented at high fl ash intensities when the eyes were dark-adapted. In light-adapted conditions, a steady background-adapting fi eld (30 cd/m 2 ) was maintained inside the Ganzfeld to continually saturate the rod system. Flash intensities and background luminance were calibrated using a research radiometer (IL1700 Photometer, International Light Inc., Newburyport, MA) with a SED033 detector placed at 36 cm from the source (at the same location as the cyclopean eye).
ERG recording
All experimental protocols followed the guidelines of the ISCEV (Marmor et al., 2009 ; Bouskila et al., 2014 ; McCulloch et al., 2015 ) . ERG recordings and signal processing ERGs were carried out in the morning. The recorded eye was covered with a corneal contact lens electrode (Jet electrodes, Diagnosys LLC, Lowell, MA) moistened with 1% carboxymethylcellulose sodium (Refresh Celluvisc, Allergan Inc., Markham, ON). The electrode was equipped with four small posts that kept the eyelid open. Reference and ground gold disc electrodes (model F-E5GH; Grass Technologies, Astro-Med, Inc., West Warwick, RI) were kept in place with adhesive paste (Ten20 conductive EEG paste, Kappa Medical, Prescott, AZ) at the external canthi and forehead, respectively. Responses were amplifi ed 10,000 times and fi ltered with a band pass from 1 to 500 Hz except for the oscillatory potentials, which were extracted with the LKC software with a band pass from 75 to 500 Hz. Each trace included a 20 ms pre-stimulus baseline. The recording protocol for assessing the effect of the drugs is summarized in Figure 1 .
Statistical analysis
For the waveform analysis, the amplitude of the a-wave was measured from the baseline to the trough of the a-wave. The amplitude of the b-wave was measured from the trough of the a-wave to the peak of the b-wave. The latency was defi ned from the onset of the fl ash to the trough (a-wave) or peak (b-wave). If these values fell within the acceptable time window (a-wave: 10-50 ms from fl ash, b-wave: 50-150 ms from fl ash), and they were within 3 s.d. above or below the mean, then they were saved. A repeated measure analysis of variance (ANOVA) was used to determine if the values extracted from the ERG curves in the DMSO-injected group were different from the LPG-injected group or the CID-injected group. Each mixed model ANOVA included one repeated measures factor (intensity of the fl ash) and one between group factors (drug: DMSO, LPG, or CID).
Results
No changes in the fundus of the eyes were observed after the intravitreal injection in any of the animals. There were also no differences in the intraocular pressure (before: 11 ± 3 mm Hg; after: 11 ± 4 mm Hg) or the pupil size (before: 8.8 ± 0.3 mm; after: 8.8 ± 0.3 mm).
LPG increases the scotopic b-wave amplitude
The effect of LPG on the scotopic ERG was comparable across monkeys. Fig. 2A illustrates the average ERG waveform in darkadapted conditions following the intravitreal injection of DMSO, LPG, or CID at 13 stimulus intensities. Each curve was generated from a simple mean across monkeys. As can be seen in the traces, the intravitreal injection of LPG increases the amplitude of the scotopic ERG. This effect was not signifi cant for the a-wave amplitude ( P = 0.972, Fig. 2B ), but was signifi cant for the b-wave amplitude ( P = 0.050, Fig. 2C ). On average, LPG caused the scotopic b-wave amplitude to increase by 36% relative to the control (DMSO). In addition, the effect was signifi cant at several specifi c fl ash intensities [−2.6 log (cd s)/m 2 , P = 0.010; −2.2 log (cd s)/m 2 , P = 0.007; −2.0 log (cd s)/m 2 , P = 0.012; −1.0 log (cd s)/m 2 , P = 0.015; −0.6 log (cd s)/m 2 , P = 0.028] and marginally signifi cant at other fl ash intensities [0 log (cd s)/m 2 , P = 0.077; 1.4 log (cd s)/m 2 , P = 0.074]. At the rod standard fl ash [−2.2 log (cd s)/m 2 ], a fl ash intensity that corresponds to rod-driven responses, the increase caused by the injection of LPG was 52 ± 18 μ V (52% relative to DMSO). At the combined rod-cone standard fl ash [0.6 log (cd s)/m 2 ], a fl ash intensity that corresponds to mixed-rod-cone responses, LPG lead to an increase of 56 ± 40 μ V (22% relative to DMSO). The latencies of LPG were comparable to DMSO [no signifi cant difference for a-wave latency ( P = 0.915, Fig. 2D ) or the b-wave latency ( P = 0.413, Fig. 2E )] . 
CID decreases the scotopic b-wave amplitude
The effect of CID on the scotopic ERG was comparable across monkeys. Fig. 2A illustrates the average ERG waveform in scotopic conditions. The most apparent feature of these curves is that the intravitreal injection of CID decreased the amplitude of the scotopic ERG. This effect was not signifi cant for the a-wave amplitude ( P = 0.197, Fig. 2B ), but was signifi cant for the b-wave amplitude ( P = 0.004, Fig. 2C ). CID had no signifi cant effect on the latency for the a-wave ( P = 0.113, Fig. 2D ) or the b-wave ( P = 0.089, Fig. 2E ). The average decrease of the scotopic b-wave amplitude was 66%.
In addition, the effect of CID on the amplitude of the b-wave was signifi cant at every individual fl ash intensity [−3.6 log (cd s)/m 2 , P = 0.003; −3.4 log (cd s)/m 2 , P = 0.003; −3.2 log (cd s)/m 2 , P = 0.002; −2.8 log (cd s)/m 2 , P = 0.018; −2.6 log (cd s)/m 2 , P = 0.003; −2.2 log (cd s)/m 2 , P = 0.001; −2.0 log (cd s)/m 2 , P = 0.006; −1.0 log (cd s)/m 2 , P = 0.027; −0.6 log (cd s)/m 2 , P = 0.024; 0 log (cd s)/m 2 , P = 0.016; 0.4 log (cd s)/m 2 , P = 0.007; 0.6 log (cd s)/m 2 , P = 0.002; 1.4 log (cd s)/m 2 , P = 0.004]. At the rod standard fl ash [−2.2 log (cd s)/m 2 ], CID decreased the b-wave amplitude by 66 ± 15 μ V (67%) relative to DMSO. At the combined rod-cone standard fl ash [0.6 log (cd s)/m 2 ], CID decreased the b-wave amplitude by 153 ± 37 μ V (59%) relative to DMSO.
The oscillatory potentials are not affected by either compound
A one-way ANOVA was performed on the summed amplitude of the oscillatory potentials at the standard fl ash [optimal intensity of 0.6 log (cd s)/m 2 ; Bee, 2001 ; Bouskila et al., 2014 ] . The results show that there was no signifi cant difference between the vehicle and the agonist for the amplitude (DMSO, x = 61.9 ± 14.4 μ V; LPG, x = 68.9 ± 11.3 μ V; P = 0.674) or latency (DMSO, x = 21.0 ± 0.6 ms; LPG, x = 20.5 ± 0.4 ms; P = 0.724). A non-signifi cant effect was also found between the vehicle and the antagonist for the amplitude (CID, x = 36.0 ± 7.9 μ V; P = 0.122) and the latency (CID, x = 18.8 ± 1.2 ms; P = 0.123).
LPG has no signifi cant effect on the photopic ERGs
The effects of LPG on the photopic ERG were comparable across monkeys. Fig. 3A illustrates the average ERG waveform across monkeys in light-adapted conditions following intravitreal injection of DMSO, LPG or CID for 12 stimulus intensities. There were no signifi cant effects of LPG for a-wave amplitude ( P = 0.817, Fig. 3B ), b-wave amplitude ( P = 0.756, Fig. 3C ), a-wave latency ( P = 0.942, Fig. 3D ), or b-wave latency ( P = 0.727, Fig. 3E ).
CID has no signifi cant effect on the photopic ERGs
The effects of CID and DMSO on the photopic ERG were comparable across monkeys, see averages plotted in Fig. 3A . There was no statistically signifi cant difference between CID and DMSO: a-wave amplitude ( P = 0.321, Fig. 3B ), b-wave amplitude ( P = 0.067, Fig. 3C ). CID also had no signifi cant effect on the a-wave latency ( P = 0.381, Fig. 3D ) or the b-wave latency ( P = 0.093, Fig. 3E ).
Discussion
This study investigated the functional consequences of monocular intravitreal injections of potent and selective GPR55 agonist (LPG) or antagonist (CID) in monkeys. Using electroretinographic recordings, we showed that under scotopic conditions, the administration of LPG signifi cantly increased the amplitude of b-wave responses while CID caused them to decrease. The scotopic latencies were not affected by either compound, and neither were the amplitudes or latencies recorded under photopic conditions. This is the fi rst evidence that GPR55 is only involved in scotopic vision since its activation by LPG, and its blockade by CID, modulated the dimlight retinal responses driven by the rod pathway. The strength of this result is visible in Fig. 4 , which depicts the relationship between the relative amplitudes of the b-and a-wave (Perlman, 1983 ) . This fi gure illustrates scotopic retinal function, and its modulation by either blocking GPR55 (impaired retinal function, e.g., nyctalopia) or by activating it (increased retinal function, e.g., hyper-scotopia). The functional effects reported here are in line with the anatomical localization of GPR55 in rod photoreceptors and confi rms its purported role in scotopic vision.
GPR55 belongs to the Class A rhodopsin-like family of G protein-coupled receptors. Expression of GPR55 in the retina is limited to rod inner segments (Bouskila et al., 2013 b ) , which is implicated in the generation of the scotopic ERG b-wave (Robson & Frishman, 1995 ; Tian & Slaughter, 1995 ) , although this is somewhat debated (Miller & Dowling, 1970 ; Wen & Oakley, 1990 ) . Given the expression pattern of GPR55 ( Fig. 5A ) , we hypothesized that antagonizing this receptor in the retina would lead to a decrease in the scotopic ERG b-wave. This is indeed what we found, which can be explained by GPR55's infl uence on the glutamate pathway (Sylantyev et al., 2013 ; Bouskila et al., 2013 b ) . We speculate that the presynaptic GPR55 in rods is coupled to G α 13 , and may have a role in the regulation of the postsynaptic mGluR6-signaling pathway in rod ON-bipolar cells. In normal conditions of dark adaptation, a large quantity of glutamate is released from rod photoreceptor terminals and binds to the metabotropic glutamate receptor mGluR6 located at the tip of ON-bipolar cell dendrites (Sampath & Rieke, 2004 ) . The activation of GPR55 in rods by LPG coupled to G α 13 , stimulates RhoA, Rho-associated protein kinase (ROCK), Phospholipase C (PLC) and opens Na + /Ca ++ channels resulting in membrane depolarization (Bouskila et al., 2013 b ) and hence an increased scotopic b-wave ( Fig. 5B ) . Following the blockade of GPR55 with CID, the hyperpolarization of rods diminishes the release of glutamate ( Fig. 5C ). The putative activation of G α 13 , RhoA, ROCK and PLC is consequently lowered resulting in the closing of Na + /Ca ++ channels, and hence a decreased scotopic ERG b-wave. Essentially, blocking GPR55 in the dark-adapted rod is like exposing it to photopic conditions (Bouskila et al., 2013 b ) . It was previously reported that failure to activate mGluR6 on rod ON-bipolar cells abolishes light responses (Sampath & Rieke, 2004 ) . Indeed, the speculation that GPR55 regulates guanosine triphosphate (GTP) hydrolysis of G α 13 is also supported by the notion that phototransduction involves G α 13 , leading to the release of glutamate ( Fig. 5 ) . A detailed characterization of other molecules that act as agonists on GPR55 will be informative for treatments of ocular diseases, since activating this protein might be able to increase photosensitivity.
Drug delivery directly into the eye in humans is a common treatment for retinal disorders. For example, intravitreal injections are often performed in the treatment of age-related macular degeneration and diabetic retinopathy (see Duvvuri et al., 2003 for review) . The effectiveness of treatments for retinal diseases has signifi cantly improved since the introduction of medications administered directly into the vitreous because of their immediate effects. This procedure is now used on a daily basis in clinics to treat these aforementioned diseases.
Night blindness (e.g., nyctalopia), a condition where it is nearly impossible to see in low light, is a symptom of many eye diseases like retinitis pigmentosa, Oguchi disease, and congenital stationary night blindness, which specifi cally targets the rods (Marc et al., 2003 ) . Given the present fi ndings, implication of GPR55 in scotopic vision might therefore be exploited as a pharmacological target in the treatment of retinal diseases that include symptoms of night blindness. showing that GPR55 is preferentially expressed in the inner segments of rod photoreceptors (upper arrow) and spherules (lower arrow). This observation is identical to the one previously reported (Bouskila et al., 2013 b ) . ( B ) Under scotopic conditions, the activation of GPR55 by LPG on rods coupled to G α 13 , RhoA, ROCK, and PLC opens Na + /Ca ++ channels resulting in the membrane depolarization (Bouskila et al., 2013 b ) and hence an increased scotopic b-wave. ( C ) Following the blockade of GPR55 with CID, the activation of G α 13 , RhoA, ROCK, and PLC is consequently lowered resulting in the closing of Na + /Ca ++ channels, and hence a decreased scotopic ERG b-wave in the CID-treated eyes. The scotopic waveforms are taken from Fig 
